MMRC announces clinical trial of pomalidomide CC-4047
Paul Richardson, MD, Clinical Director of the Jerome Lipper Center for Multiple Myeloma at DanaFarber Cancer Institute, is leading the multicenter, randomized, open-label, dose-escalation study. A Phase 1 study is designed to determine maximum tolerated dose of single-agent pomalidomide while a Phase 2 randomized study will compare the oral compound's efficacy alone against its combination with dexamethasone.
"This potent new immunomodulator, which is in the same class as thalidomide and lenalidomide, will hopefully be successful in treating patients who have relapsed or who don't respond to currently available treatment options. We are excited to be testing pomalidomide in this context and are optimistic that it will meaningfully add to our therapeutic options for our patients," said Dr. Richardson.
Pomalidomide is an IMiDs compound, a member of Celgene's proprietary group of novel oral immunomodulatory agents that impede or stabilize disease through several mechanisms of action, including anti-angiogenic activity.
Celgene's lead IMiDs compound, REVLIMID (lenalidomide) continues to demonstrate unprecedented overall survival in multiple myeloma as well as significant clinical potential across a broad range of blood cancers.
IMiDs compounds are proprietary novel small molecule, orally available compounds that modulate the immune system and other biologically important targets through multiple mechanisms of action, including angiogenesis inhibition, modulation of the levels of key pro-inflammatory and regulatory cytokines and immune cell co-stimulation.
"This potent new immunomodulator, which is in the same class as thalidomide and lenalidomide, will hopefully be successful in treating patients who have relapsed or who don't respond to currently available treatment options. We are excited to be testing pomalidomide in this context and are optimistic that it will meaningfully add to our therapeutic options for our patients," said Dr. Richardson.
Pomalidomide is an IMiDs compound, a member of Celgene's proprietary group of novel oral immunomodulatory agents that impede or stabilize disease through several mechanisms of action, including anti-angiogenic activity.
Celgene's lead IMiDs compound, REVLIMID (lenalidomide) continues to demonstrate unprecedented overall survival in multiple myeloma as well as significant clinical potential across a broad range of blood cancers.
IMiDs compounds are proprietary novel small molecule, orally available compounds that modulate the immune system and other biologically important targets through multiple mechanisms of action, including angiogenesis inhibition, modulation of the levels of key pro-inflammatory and regulatory cytokines and immune cell co-stimulation.
posted by gwg at 11:09 AM
0 Comments:
Post a Comment
<< Home